| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Cytek Biosciences, Inc. | Director | Stock Option (right to buy) | 30,242 | 14 Jun 2023 | Direct | ||
| Inhibikase Therapeutics, Inc. | Director | Stock Option (right to buy) | 30,000 | 16 Jul 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | 16 Jul 2024 | 1 | $0 | 4 | Director | 18 Jul 2024, 17:23 |
| IKT | Inhibikase Therapeutics, Inc. | 30 Jun 2023 | 1 | $0 | 4 | Director | 05 Jul 2023, 21:16 |
| CTKB | Cytek Biosciences, Inc. | 14 Jun 2023 | 1 | $0 | 4 | Director | 16 Jun 2023, 18:36 |
| IKT | Inhibikase Therapeutics, Inc. | 01 Sep 2022 | 1 | $0 | 4 | Director | 06 Sep 2022, 17:08 |
| IKT | Inhibikase Therapeutics, Inc. | 01 Sep 2022 | 0 | $0 | 3 | Director | 06 Sep 2022, 17:06 |
| CTKB | Cytek Biosciences, Inc. | 01 Jun 2022 | 1 | $0 | 4 | Director | 03 Jun 2022, 17:36 |
| CTKB | Cytek Biosciences, Inc. | 22 Jul 2021 | 1 | +$85,000 | 4 | Director | 27 Jul 2021, 21:00 |
| CTKB | Cytek BioSciences, Inc. | 22 Jul 2021 | 0 | $0 | 3 | Director | 22 Jul 2021, 21:07 |